Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

  • WCLC 2016

    17th World Conference on Lung Cancer

    Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria

    Presentation Date(s):  
    • Dec 4 - 7, 2016
    • Total Presentations: 2466

    To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.

    Presentations will be available 24 hours after their live presentation time

    IASLC Member Price: $0.00 USD
    Enter Virtual Meeting Access Code
Filter Results:

Show Only Available Presentations

  • +

    OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC

    • Type: Oral Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 8
    • Moderators:L. Crinò
    • Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
    • +

      OA03.07 - KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab 

      12:05 - 12:15  |  Author(s): R. Herbst

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    OA05 - Treatment Advances in SCLC

    • Type: Oral Session
    • Track: SCLC/Neuroendocrine Tumors
    • Presentations: 8
    • Moderators:A. Ardizzoni
    • Coordinates: 12/05/2016, 14:20 - 15:50, Strauss 2
    • +

      OA05.01 - Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028 (Abstract under Embargo until December 5, 7:00 CET)

      14:20 - 14:30  |  Author(s): P.A. Ott

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MA05 - Innovative Techniques in Pulmonology and the Impact on Lung Cancer

    • Type: Mini Oral Session
    • Track: Pulmonology
    • Presentations: 12
    • Moderators:J. Eckmayr
    • Coordinates: 12/05/2016, 16:00 - 17:30, Strauss 1
  • +

    OA08 - Targeted Therapies in Brain Metastases

    • Type: Oral Session
    • Track: Advanced NSCLC
    • Presentations: 8
    • Moderators:D. Ball
    • Coordinates: 12/05/2016, 16:00 - 17:30, Schubert 1
  • +

    SC11 - ALK, ROS1 and Rare Mutations in NSCLC

    • Type: Science Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 5
    • Moderators:D. Kim
    • Coordinates: 12/05/2016, 16:00 - 17:30, Lehar 1-2
  • +

    MA07 - ALK-ROS1 in Advanced NSCLC

    • Type: Mini Oral Session
    • Track: Advanced NSCLC
    • Presentations: 12
    • Moderators:N. Singh
    • Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
  • +

    P2.03a - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 72
    • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P2.03a-038 - Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70

      14:30 - 14:30  |  Author(s): D.H. Lee

      • Abstract

      Loading...

    • +

      P2.03a-061 - Randomized Phase II Trial Comparing Intercalation of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy

      14:30 - 14:30  |  Author(s): S. Yoon

      • Abstract

      Loading...

  • +

    P2.06 - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
    • Presentations: 47
    • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P2.06-017 - Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET

      14:30 - 14:30  |  Author(s): L. Bazhenova

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    OA23 - EGFR Targeted Therapies in Advanced NSCLC

    • Type: Oral Session
    • Track: Advanced NSCLC
    • Presentations: 8
    • Moderators:O.T. Brustugun
    • Coordinates: 12/07/2016, 14:20 - 15:50, Stolz 2
    • +

      OA23.05 - First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7

      15:05 - 15:15  |  Author(s): K. Park

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    P3.02a - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 37
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02a-013 - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

      14:30 - 14:30  |  Author(s): D..R. Camidge

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      P3.02a-016 - Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)

      14:30 - 14:30  |  Author(s): J.C. Yang

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      P3.02a-018 - Efficacy of Pemetrexed Based Chemotherapy Compared with Non-Pemetrexed Based Chemotherapy in Advanced, ALK-Positive NSCLC

      14:30 - 14:30  |  Author(s): J. Jo

      • Abstract

      Loading...

    • +

      P3.02a-036 - Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC

      14:30 - 14:30  |  Author(s): R. Dziadziuszko

      • Abstract

      Loading...